Children with Hurler syndrome (mucopolysaccharidosis type IH (MPSIH)) have skeletal, joint and soft tissue abnormalities that may persist or progress after hematopoietic stem cell transplantation (HSCT). We report our single center experience with development of carpal tunnel syndrome (CTS) in 43 children with MPSIH after HSCT. Twenty-three children (59%) developed CTS following HSCT; 19 of the 39 children with enzyme activity in the normal or heterozygous range developed CTS (49%), whereas all four children with low heterozygous or absent enzyme activity developed CTS after HSCT. Fourteen of 19 related donor marrow recipients, eight of 19 of those receiving an unrelated donor graft and one of five unrelated cord blood recipients developed CTS. The mean age at surgical release was 4.8 years. With each year increase in age at HSCT, there was a 55% increased risk. Age and enzyme activity after HSCT were significant factors in the development of CTS. Transplantation by 2 years of age reduced the risk of developing CTS by 46%; higher enzyme activity led to a 78% reduction in the risk of developing CTS. However, children transplanted for MPSIH remain at risk for the development of CTS, and should be monitored on an ongoing basis by nerve conduction velocity testing.
Introduction
Hurler syndrome (mucopolysaccharidosis type IH, MPSIH) is an autosomal recessive, inherited metabolic storage disorder due to a deficiency of the enzyme a-Liduronidase, resulting in the systemic accumulation of the glycosaminoglycans dermatan sulfate and heparan sulfate. Clinical manifestations include progressive hepatosplenomegaly, cardiac disease with coronary and valvular insufficiency, airway compromise, vision and hearing impairment, severe skeletal abnormalities, progressive mental retardation, hydrocephalus and premature death with a median life span of 5 years. 1 Allogeneic hematopoietic cell transplantation (HSCT) is the only therapy for MPSIH proven to prolong survival and either reverse or stabilize disease manifestations. [2] [3] [4] [5] Worldwide experience with more than 300 children with Hurler syndrome shows that HSCT can promote long-term survival, [2] [3] [4] [5] [6] stabilize cognitive function 5, 7, 8 and prevent fatal cardio-pulmonary complications. 9 However, orthopedic manifestations of MPSIH may progress owing to the accumulation of specific mucopolysaccharides in cartilage, tendon and joint capsule tissue. The findings of dysostosis multiplex in MPSIH includes: carpal tunnel syndrome (CTS), trigger digits, shortened stature, thoracolumbar kyphosis, genu valgum, developmental dysplasia of the hip and diminished endochondral ossification for longitudinal bone growth and joint stiffness. [10] [11] [12] [13] CTS can cause severe compression of the median nerve. As reported, most children with Hurler syndrome develop CTS but rarely have specific complaints of hand pain or numbness until severe nerve compression exists. 2, 10, [12] [13] [14] [15] [16] [17] [18] Early in our experience of evaluating and treating CTS, the diagnosis was often delayed until sensory complaints, pain or profound motor atrophy of the thenar muscles was observed. This delay could result in irreversible nerve damage. Thus, in 1996, we initiated nerve conduction velocity (NCV) testing to screen all patients with MPS disorders for CTS. Prolonged sensory and motor NCV testing for the median nerve across the carpal tunnel, when compared to sensory and motor NCV of the ulnar nerve over the same length segment, indicated the presence of CTS, even in the absence of specific clinical complaints. In a previous analysis of 15 patients who had undergone bone marrow transplantation before 1995, the incidence of the development of CTS was 73%. 12 The goal of this study was to retrospectively evaluate patient and HSCT characteristics that predicted the development of CTS. We hypothesized that patients who had a normal or heterozygous level of enzyme after HSCT would be at less risk for development of CTS.
Patients and methods
All children with Hurler syndrome transplanted at the University of Minnesota between 1987 and April 2002 underwent chart review, using the following criteria for inclusion into the study: (1) the establishment of the diagnosis of MPSIH by clinical evaluation and enzyme level; (2) patients must have survived at least 1 year after first or second HSCT; (3) an evaluation must have been performed for CTS by surface electrode testing; and (4) the patient had been examined by one of the authors. Fortythree children met these criteria and were included in this study.
Factors evaluated in the analysis included patient age at HSCT, stem cell source, cell dose (nucleated cells/kg, bone marrow only), donor engraftment status, a-L-iduronidase enzyme level post HSCT, results of NCV testing, presence or absence of CTS and age at CTS surgery, if surgery was performed.
All patients received high-dose chemotherapy with or without radiation followed by related (n ¼ 19), unrelated donor (n ¼ 19) or unrelated cord blood (n ¼ 5) transplantation. Parental consent was obtained for all patients and protocols were approved by the University of Minnesota Institutional Review Board. Patient characteristics are presented in Table 1 . Engraftment was assessed by measuring leukocyte a-L-iduronidase enzyme activity and molecular testing (variable nucleotide tandem repeat (VNTR) or semiquantitative restriction fragment length polymorphism (RFLP)) analysis. The a-L-iduronidase enzyme activity was determined over the time span associated with this study and was performed in three different laboratories, using different methodologies. 19, 20 Enzyme activity levels are reported as normal, heterozygous (25-60% of normal), low heterozygous (10-25% of normal) or absent (o2% of normal) was assigned according to the laboratory's reference ranges.
Diagnosis of CTS was based on results of NCV testing. CTS was defined as significant slowing for motor and/or sensory NCV across the carpal tunnel for the median nerve compared to the ulnar nerve, over the same length segment. If CTS was diagnosed by NCV testing, treatment was surgical release. 12 NCV studies were compared before and after CTS surgery.
The following factors were analyzed with respect to CTS: univariate testing was performed comparing the level of a-L-iduronidase activity (patients with normal or heterozygous levels vs patients with low heterozygous or absent levels), age at transplantation (o2 years of age vs 42 years), stem cell source (related donor vs unrelated donor vs unrelated cord blood) and the cell dose of marrow recipients (o3.5 Â 10 8 nucleated cells/kg recipient body weight vs a cell dose of 43.5 Â 10 8 nucleated cells/kg) for those receiving a matched related or unrelated donor graft.
Data were analyzed using descriptive statistics, w 2 , Spearman's correlation coefficients, logistic regression and Kaplan-Meier analysis of probability. Statistical Package for Social Sciences (SPSS, Chicago, IL, USA) v.11.5 software was used to perform statistical analyses.
Results
Twenty-three of 43 children (53%) with Hurler syndrome developed CTS following HSCT. The mean age at time of surgical release was 4.8 years (range, 2.5-10.9). The following univariate factors were analyzed comparing the group developing CTS (n ¼ 23) to the group without CTS (n ¼ 20).
a-L-iduronidase enzyme activity
Of the 43 children in the study, 39 had normal or heterozygous levels of enzyme activity, whereas four had low heterozygous or absent enzyme activity at latest followup after HSCT. Nineteen of the 39 (49%) children with normal or heterozygous enzyme activity developed CTS, whereas in contrast, all four (100%) patients with absent or low heterozygous enzyme activity developed CTS (P ¼ NS).
Source of stem cells and bone marrow nucleated cell dose
Fourteen of 19 (74%) patients who underwent related donor bone marrow HSCT developed CTS. Eight of 19 (42%) patients who received unrelated donor bone marrow transplantation developed CTS. One of five (20%) patients who had an unrelated cord blood transplantation developed CTS (P ¼ NS). There was no correlation with bone marrow nucleated cell dose and the development of CTS. The findings that the risk of developing CTS can be influenced by both the age at HSCT and by achieving normal or heterozygous enzyme activity suggests that there is a benefit of HSCT in decreasing the risk of median nerve constriction due to thickening transverse carpal ligaments and flexor tenosynovial deposits seen as a result of the disease. 12 Although there is no data to document the incidence of CTS in non-transplanted Hurler patients, the development of this complication in four of four patients with very low or absent enzyme activity suggests that the incidence is high.
We hypothesized that Hurler patients who had a normal or carrier level of a-L-iduronidase enzyme following HSCT would have either a delayed onset of CTS or not develop median nerve dysfunction. We found no statistical significant difference between the development of CTS when patients with normal vs heterozygous enzyme activity are compared. Although the number of patients with low heterozygous or absent level enzyme activity was limited (n ¼ 4), the observance of CTS in all of these patients suggests that achieving a threshold enzyme level in the heterozygous range is important in decreasing the likelihood of CTS. There was a trend towards increased time to onset of CTS in patients with higher enzyme activity after HSCT, although an absolute enzyme value providing maximal benefit cannot be determined with this small cohort.
We examined the importance of age at HSCT, having noted that patients with Hurler syndrome transplanted before 2 years of age had improved disease-specific outcomes. 3, 5 There was a statistically significant difference between the age at HSCT and the age at the time of CTS surgery in a univariate analysis (P ¼ 0.007).
A third variable examined in this study was the source of the hematopoietic stem cell graft. When correlating the hematopoietic stem cell sources (cord blood, unrelated and related donor bone marrow) with the occurrence of CTS surgery, we found a statistically significant difference between the source of stem cells and occurrence of carpal tunnel surgery (P ¼ 0.04). In addition to the Spearman's r correlations, a Kruskal-Wallis test for significance was also performed, as a more accurate means of examining differences between the three groups. Owing to small sample size, the P-value was 0.058, bordering on significance. A larger sample is needed to probe the specific differences between the stem cell source groups.
The fourth variable examined was cell dose in relation to the occurrence of CTS surgery. We grouped patients into those with less than and those with greater than a cell dose of 3.5 Â 10 8 NC/kg. There was no statistically significant difference between these groups and the requirement for CTS surgery.
Children who did not need CTS surgery vs those who did were compared by (Figure 1 ) Kaplan-Meier probability analysis. Age at HSCT and higher enzyme activities were both shown to decrease the risk of developing CTS. These results supported our hypothesis that patients with Hurler syndrome who had a normal or heterozygous level of a-L-iduronidase enzyme activity following HSCT would have either delayed onset of CTS or no CTS.
In summary, our data suggests that early HSCT decreases the risk of CTS and that this is dependent on achieving a heterozygous or normal level of enzyme following HSCT. We believe it is advisable for all patients with Hurler syndrome to undergo NCV studies beginning 1 year after HSCT and annually thereafter, as it is clear that many will develop CTS despite a successful transplant. Many of these patients are not able to describe the classic CTS symptoms of paresthesia and pain, and therefore the clinical history and physical examination are insufficiently sensitive to diagnose CTS early. NCV studies provide the best protection against the possibility of irreversible nerve damage. The surgery is well tolerated, and none of the individuals treated surgically developed thenar wasting or sensory loss, as it has been observed previously in these children. 
